AI assistant
GENEDRIVE PLC Director's Dealing 2022
7668_dirs_2022-02-23_ad590c4a-2a13-4af2-a811-f47d7327b9cc.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 6136C
Genedrive PLC
23 February 2022
23 February 2022
genedrive plc
("genedrive" or the "Company")
Director/PDMR Notification
genedrive plc (AIM: GDR), the near patient molecular diagnostics company, makes the following announcement regarding a transaction in the Company's ordinary shares by Matthew Fowler, outgoing Chief Financial Officer.
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
1.
Details of the person discharging managerial responsibilities / person closely associated
a.
Name
Matthew Fowler
2.
Reason for the notification
a.
Position/status
Chief Financial Officer
b.
Initial notification
/Amendment
Initial
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
genedrive plc
b.
LEI
213800ZYODIRZ87Y4K14
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the
Financial instrument, type
of instrument
Identification code
Ordinary Shares of 1.5p each
GB00B1VKB244
b.
Nature of the transaction
Disposal of ordinary shares
c.
Price(s) and volume(s)
| Price(s) | Volume(s) |
| 17.5p | 86,957 |
d.
Aggregated information
· Aggregated volume
· Price
86,957 Ordinary Shares
17.5p per Ordinary Share
e.
Date of the transaction
23 February 2022
f.
Place of the transaction
London Stock Exchange, AIM Market (XLON)
For further details please contact:
| genedrive plc | +44 (0)161 989 0245 |
| David Budd: CEO / Matthew Fowler: CFO | |
| Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 |
| James Steel | |
| finnCap (Joint Broker) | +44 (0)20 7220 0500 |
| Geoff Nash / Kate Bannatyne / Alice Lane | |
| Walbrook PR Ltd (Media & Investor Relations) | +44 (0)20 7933 8780 or [email protected] |
| Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 |
About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets and a high throughput SARS-CoV-2 assay. The Company has also recently launched a test to help in the prevention of hearing loss caused by certain antibiotics in neonates.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHEASADASXAEFA